NASDAQ : INBX
Inhibrx Biosciences, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 73.65 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.08B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.06B |
| Enterprise Value | 1.11B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 14.72M |
| Shares Outstanding | 14.72M |
| Shares Change (YoY) | +0.61% |
| Shares Change (QoQ) | +0.54% |
| Owned by Insiders (%) | 15.62% |
| Owned by Institutions (%) | 70.30% |
| Float | 8.58M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 168.18 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.07 |
| Quick Ratio | 4.76 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.21 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -1,773.60% |
| Return on Assets (ROA) | -43.61% |
| Return on Invested Capital (ROIC) | -90.13% |
| Return on Capital Employed (ROCE) | -101.31% |
| Weighted Average Cost of Capital (WACC) | 22.59% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.26M |
| Employee Count | 110 |
| Asset Turnover | n/a |
| Inventory Turnover | 55.75 |
Taxes
| Measure | Value |
|---|
| Income Tax | 3,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 3.82 |
| 52-Week Price Change | -11.81% |
| 50-Day Moving Average | 101.71 |
| 200-Day Moving Average | 92.14 |
| Relative Strength Index (RSI) | 31.49 |
| Average Volume (20 Days) | 282,425 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.42M |
| Short Previous Month | 3.43M |
| Short % of Shares Out | 23.22% |
| Short % of Float | 39.83% |
| Short Ratio (days to cover) | 13.62 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -103.00M |
| Operating Income | -127.81M |
| Pretax Income | -138.18M |
| Net Income | -138.18M |
| EBITDA | -125.60M |
| EBIT | -127.81M |
| Earnings Per Share (EPS) | -$8.88 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 133.34M |
| Total Debt | 181.63M |
| Net Cash | -48.28M |
| Net Cash Per Share | -$3.28 |
| Equity (Book Value) | -52.98M |
| Book Value Per Share | -3.60 |
| Working Capital | 114.15M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -131.89M |
| Capital Expenditures | -10,000 |
| Depreciation & Amortization | 2.21M |
| Net Borrowing | 74.99M |
| Free Cash Flow | -131.90M |
| FCF Per Share | -$8.96 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.61% |
| Shareholder Yield | -0.61% |
| Earnings Yield | -12.30% |
| FCF Yield | -12.35% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $266.67 |
| Price Target Difference | 269.55% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 352.95% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -1.92 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |